ProCE Banner Activity

Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

Conference Coverage
Podcast Episodes
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss practice‑changing data for gynecologic cancers presented at the virtual IGCS 2021 annual meeting, including novel data for single-agent and combination immunotherapy in patients with endometrial and cervical cancers, subanalyzes of exceptional responders to PARP inhibitors in ARIEL3, and timing for initiation of PARP inhibitor maintenance from the NORA trial.

Released: September 21, 2021

Expiration: September 20, 2022

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Supporters

This educational activity is supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Tesaro; consulting fees from Ability, AstraZeneca, Biocad, Clovis, Merck Serono (paid to her institution), MSD, Seattle Genetics, Tesaro, and Zentalis; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Tesaro.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.